Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

Melissa J. Karau, Suzannah M. Schmidt-Malan, Qun Yan, Kerryl E. Greenwood-Quaintance, Jayawant Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, Robin Patel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.

Original languageEnglish (US)
Article numbere01235-19
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number10
DOIs
StatePublished - Jan 1 2019

Fingerprint

Daptomycin
Osteomyelitis
Methicillin-Resistant Staphylococcus aureus
Anti-Infective Agents
Bacteriophages
Bacteria
Bone and Bones

Keywords

  • CF-301
  • Daptomycin
  • Exebacase
  • Methicillin-resistant Staphylococcus aureus
  • Osteomyelitis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats. / Karau, Melissa J.; Schmidt-Malan, Suzannah M.; Yan, Qun; Greenwood-Quaintance, Kerryl E.; Mandrekar, Jayawant; Lehoux, Dario; Schuch, Raymond; Cassino, Cara; Patel, Robin.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 10, e01235-19, 01.01.2019.

Research output: Contribution to journalArticle

Karau, Melissa J. ; Schmidt-Malan, Suzannah M. ; Yan, Qun ; Greenwood-Quaintance, Kerryl E. ; Mandrekar, Jayawant ; Lehoux, Dario ; Schuch, Raymond ; Cassino, Cara ; Patel, Robin. / Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats. In: Antimicrobial Agents and Chemotherapy. 2019 ; Vol. 63, No. 10.
@article{078b93040260416e8a20c5301c6bc1f9,
title = "Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats",
abstract = "Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.",
keywords = "CF-301, Daptomycin, Exebacase, Methicillin-resistant Staphylococcus aureus, Osteomyelitis",
author = "Karau, {Melissa J.} and Schmidt-Malan, {Suzannah M.} and Qun Yan and Greenwood-Quaintance, {Kerryl E.} and Jayawant Mandrekar and Dario Lehoux and Raymond Schuch and Cara Cassino and Robin Patel",
year = "2019",
month = "1",
day = "1",
doi = "10.1128/AAC.01122-19",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

AU - Karau, Melissa J.

AU - Schmidt-Malan, Suzannah M.

AU - Yan, Qun

AU - Greenwood-Quaintance, Kerryl E.

AU - Mandrekar, Jayawant

AU - Lehoux, Dario

AU - Schuch, Raymond

AU - Cassino, Cara

AU - Patel, Robin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.

AB - Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.

KW - CF-301

KW - Daptomycin

KW - Exebacase

KW - Methicillin-resistant Staphylococcus aureus

KW - Osteomyelitis

UR - http://www.scopus.com/inward/record.url?scp=85072563069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072563069&partnerID=8YFLogxK

U2 - 10.1128/AAC.01122-19

DO - 10.1128/AAC.01122-19

M3 - Article

C2 - 31358593

AN - SCOPUS:85072563069

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

M1 - e01235-19

ER -